cagrilintide novo fda Nordisk Submits CagriSema for FDA Approval for Obesity Treatment Cagrilintide lowers bodyweight through brain

There is no established equivalence between oral and injectable tirzepatide doses

This is also the structure Novo Nordisk's own investigational semaglutide+cagrilintide combination used in REDEFINE 1 (Garvey et al., NEJM 2025) both components stepped in parallel through a 16-week ramp rather than introduced together at maintenance

Transitioning between vials When your current vial runs low and you open a new one, maintain the same concentration

No randomized trials No controlled studies No validated imaging or outcome measures Only one very small, biased case series 2

Miles EA, Calder PC

You're on The Path - a personal journey to get smarter, stronger, smarter, healthier better